Skip to main content

Recent News

IL-6 Inhibition in Refractory Systemic Sclerosis

Sep 22, 2021

A small, single-center cohort analysis of difficult, refractory systemic sclerosis (SSc) patients showed that treatment with tocilizumab (TCZ), an interleukin-6 inhibitor, resulted in significant improvement in joint and skin involvement, regardless of SSc disease duration or subtype. 

Read Article
Dr. Calabrese shares his Delta COVID-19 breakthrough story on the blog today. https://t.co/timjB2YPys https://t.co/6w6eQncQ8Z
Dr. John Cush @RheumNow (  View Tweet)
Sep 22, 2021
FDA approves Jakafi for chronic GVHD. Ruxolitinib (Jakafi, Incyte), an oral Janus kinase 1/2 inhibitor, previously received approval for treatment of patients aged 12 years or older with steroid-refractory acute GVHD. https://t.co/isItDebNZ8

Dr. John Cush @RheumNow (  View Tweet)

Sep 22, 2021
Insurance data (biologics only given to refractory pts) study of 249 (TKR) & 159 (THR) surgeries in ~6000 #RA pts. Pts on biologics had signif less TKR (aHR: 0.55) & THR (0.63) vs higher rates if on MTX, steroids, biologic switch or APL syndr https://t.co/4rwuYswqz7

Dr. John Cush @RheumNow (  View Tweet)

Sep 22, 2021
Retrosp. review of 10–24 yr olds w/ newly Dx #SLE shows 78% given steroid-sparing DMARDs by year 1; Most (69%) given HCQ & fewer (34%) given other immunosuppressants. Adults less likely to recv immDMARDs @1 yr https://t.co/aLi6FXlMd3

Dr. John Cush @RheumNow (  View Tweet)

Sep 22, 2021
VAMC case controlled study shows CPPD pts have nohigher risk for MACE. 23,124 CPPD vs 86,629 non-CPPD, w/ >250,000 Pt-Yrs FU. CPPD MACE risk not increased (HR 0.98), but there was incr risk of MI, CVA & acute coronary syndr. https://t.co/pgmZBxTg9O Conclusions

Dr. John Cush @RheumNow (  View Tweet)

Sep 22, 2021
Prospective study of 77 RA patients in remission --> vax w/ BNT162b2 (BioNTech-Pfizer) (w/ temp D/C of DMARDs per ACR) found a vaccine-related flare rate of 7/8% (6 pts) w/ 5/6 flares after 2nd dose (2.6 days), resolved w/in 2 wks https://t.co/YOL3YVS2ne

Dr. John Cush @RheumNow (  View Tweet)

Sep 22, 2021

High Comorbidity Rates with Inclusion Body Myositis

Sep 21, 2021

Inclusion body myositis (IBM) patients tend to be older than those with idiopathic inflammatory myositis (IIM), but the scope of disease beyond their myositis is not appreciated. Now, a population-based, case-control study suggests both a lower overall survival and high comorbidity burden in IBM patients.

Read Article
Regarding Pfizer 1133 tofacitinib Safety study and recent FDA JAKi warnings -- Dr. Roy Fleischmann has said, "“There is a small increase in risk,” “But is it clinically meaningful?”, Read full interview here https://t.co/2Wd5h69Dfq

Dr. John Cush @RheumNow (  View Tweet)

Sep 21, 2021
MMWR reports real world vax efficacy in 3,689 adults (21 states) found better results w/ Moderna (93%) than Pfizer (88%) than Janssen (71%). 2 dose mRNA vaccines were more effective than 1 dose Janssen COVID vaccine https://t.co/phmPdB9dTW

Dr. John Cush @RheumNow (  View Tweet)

Sep 21, 2021
Lupus Research Alliance has awarded $3 million Global Team Science Awards to Drs Virginia Pascual (Weill Cornell Med Schoo) and Ignacio Sanz (Emory Univ Medial School) for their proposed collaborative, translational lupus projects. https://t.co/ecMlHiZfwe

Dr. John Cush @RheumNow (  View Tweet)

Sep 21, 2021
Maker Trade name Generic PFIZER Comirnaty Pfizer-BioNTech COVID-19 Vaccine FDA approved MODERNA Spikevax Moderna COVID-19 Vaccine - EUA currently J&J (pending) Janssen COVID-19 Vaccine- EUA currently https://t.co/MM7XiSCczl

Dr. John Cush @RheumNow (  View Tweet)

Sep 21, 2021
Interested in becoming a rheumatologist? It’s interview season! Dr. Kathryn Dao (@KDAO2011 ) shares tips for the interviewer AND the candidate. #RheumNow #RheumTwitter https://t.co/eWQs9CwqSm https://t.co/7FrkCWoAe8
Dr. John Cush @RheumNow (  View Tweet)
Sep 21, 2021

Worrisome Maternal Mortality with COVID-19 Infection

Sep 20, 2021

Maternal and fetal outcomes during the COVID-19 pandemic have not been well studied; yet a new retrospective study from Mexico indicates that during the pandemic maternal mortality increased by nearly 57%, with COVID-19 as the cause in 23% of cases.

This surveillance study examined maternal mortality was between February 2020–February 2021 in Mexico, with a focus on COVID-19 in pregnant women, and their outcomes.

Read Article
Addendum: Other conditions w/ a 1.2-2 fold higher risk of COVID death (admission) were CKD, hematologic cancer, epilepsy, COPD, CVD, stroke, atrial fibrillation, CHF, thromboembolism, PVD, type 2 diabetes. https://t.co/bbDsb1zLhX

Dr. John Cush @RheumNow (  View Tweet)

Sep 20, 2021
Addendum: COVID deaths increased w/ age, deprivation, male, Indian & Pakistanis. Highest risk w/ Down’s syndr (HR 12.7), renal transplant (8.1), sickle cell (7.7), Nursing home (4.1), chemotherapy (4.3), HIV/AIDS (3.3), liver cirrhosis (3), CNS dz (2.6) https://t.co/bbDsb1zLhX

Dr. John Cush @RheumNow (  View Tweet)

Sep 20, 2021
Breakthrough infections from UK QResarch database: Among 6.95 million vaccinated, 74.1% recv two vaccine doses, there were 2031 covid-19 deaths & 1929 hosp admissions; ~4.0% deaths & admissions were >14 days after 2nd dose https://t.co/bbDsb1zLhX

Dr. John Cush @RheumNow (  View Tweet)

Sep 20, 2021
Have you seen this download? How to define difficult RA--download now. https://t.co/6WGMEieHvK https://t.co/yYZdfyUQu0
Dr. John Cush @RheumNow (  View Tweet)
Sep 20, 2021
Claims case-controlled study shows statin use does not increase the risk of #RA - 32,726 RA and matched controls ; statin use (34 vs 32%) slightly increased RA risk (OR 1.12, 1.06–1.18), but signif lost after correcting for hyperlipidemia https://t.co/EcTlyE1MPx

Dr. John Cush @RheumNow (  View Tweet)

Sep 20, 2021
Analysis of existing #COVID data - as of 7/15/21, 114.9 million adults infected with COVID-19 in US. Overall population immunity (Infx+vax) is 62%, highest in adults >65yrs (77.2%); lowest in children <12 yrs (17.9%) https://t.co/EYiBUaQBLY

Dr. John Cush @RheumNow (  View Tweet)

Sep 20, 2021
×